Bioavailability and Bioequivalence Studies (BA/BE)

Designing Bioequivalence Studies for Locally Acting Drugs: Regulatory and Clinical Considerations

Posted on digi By digi

Unlike systemically absorbed drugs where bioequivalence (BE) is established through pharmacokinetic (PK) parameters like Cmax and AUC, locally acting drug products require unique BE study designs. These drugs—such as ophthalmic drops, nasal sprays, dermatological creams, inhalers, and gastrointestinal (GI)-acting formulations—are intended to exert their effect directly at the site of application, with minimal or no systemic absorption.
Click to read the full article.

Bioavailability and Bioequivalence Studies (BA/BE), Study Design Considerations

Developing Bioanalytical Methods for BE Studies: Strategy, Validation, and Regulatory Alignment

Posted on digi By digi

Bioequivalence (BE) studies rely on precise and accurate measurement of drug concentrations in biological matrices, typically plasma or serum. This requires robust, reproducible, and validated bioanalytical methods, most commonly using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Regulatory agencies such as the FDA, EMA, and CDSCO require that all bioanalytical methods used in BE trials meet stringent validation criteria to ensure data integrity and subject safety.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Selectivity and Sensitivity in LC-MS/MS Assays for BA/BE Studies

Posted on digi By digi

Bioequivalence (BA/BE) studies rely on accurate quantification of drug concentrations in biological matrices, typically human plasma. This is achieved through advanced bioanalytical techniques, predominantly LC-MS/MS (liquid chromatography–tandem mass spectrometry). Two of the most critical attributes of any bioanalytical method are selectivity—the ability to distinguish the analyte from other components—and sensitivity—the lowest amount of analyte that can be reliably measured.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Matrix Effect and Recovery Assessment Techniques in Bioanalytical Validation

Posted on digi By digi

Matrix effect and recovery are two essential parameters in bioanalytical method validation, especially in the context of LC-MS/MS assays used for bioavailability and bioequivalence (BA/BE) studies. These parameters influence method reproducibility, accuracy, and ultimately the credibility of pharmacokinetic data submitted to regulatory agencies.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Accuracy and Precision in Bioanalytical Validation for BA/BE Studies

Posted on digi By digi

In bioavailability and bioequivalence (BA/BE) studies, the quantification of drug levels in biological matrices—primarily plasma—is a critical component. Regulatory authorities such as the FDA, EMA, and CDSCO mandate stringent validation of bioanalytical methods to ensure that generated pharmacokinetic (PK) data are both reliable and reproducible. Two essential pillars of bioanalytical validation are accuracy and precision.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Stability Studies in Bioanalysis for BA/BE: Regulatory Expectations and Methodologies

Posted on digi By digi

Stability studies are a critical part of bioanalytical method validation in bioavailability and bioequivalence (BA/BE) trials. The integrity of pharmacokinetic (PK) data heavily depends on the chemical stability of the analyte in biological matrices under various conditions. These studies ensure that drug concentration measurements in plasma or serum remain accurate throughout the sample collection, storage, handling, and analysis processes.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Validation of Calibration Curves and QC Samples in Bioanalytical Methods for BA/BE

Posted on digi By digi

In bioavailability and bioequivalence (BA/BE) studies, accurate and reproducible measurement of drug concentrations in biological matrices—usually plasma—is paramount. These measurements are based on analytical runs anchored by calibration curves and quality control (QC) samples. Together, they form the backbone of data reliability, ensuring that quantitation remains within regulatory compliance.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Partial vs Full Method Validation in Bioanalytical Studies: Regulatory Perspectives and Use Cases

Posted on digi By digi

Method validation ensures that a bioanalytical method is suitable for its intended purpose—most notably, measuring drug concentrations in biological matrices in Bioavailability and Bioequivalence (BA/BE) studies. Validation requirements are defined by global regulatory bodies such as the FDA, EMA, and CDSCO.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Cross-Validation Between Analytical Labs in BA/BE Studies: Regulatory Requirements and Implementation

Posted on digi By digi

In bioavailability and bioequivalence (BA/BE) studies, sample analysis is often outsourced or shared across multiple analytical laboratories. This can be due to operational constraints, global development programs, or regulatory requirements. In such scenarios, it becomes essential to ensure method reproducibility across labs through a process known as cross-validation.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Acceptance Criteria for Sample Reanalysis in BA/BE Studies: Regulatory Expectations and Best Practices

Posted on digi By digi

Sample reanalysis is an essential component of bioanalytical integrity in bioavailability and bioequivalence (BA/BE) studies. It ensures the accuracy and reproducibility of drug concentration measurements in biological matrices, often plasma or serum. However, reanalyzing samples is not a casual activity — regulatory agencies have placed stringent controls and expectations around it to prevent selective or biased data reporting.
Click to read the full article.

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)